Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis
| Autor: | M. D. Taylor, Roger J. Leicester, Alan J Lobo, J. R. B. Green, G. D. Kerr, Humphrey Hodgson, Charles D. Holdsworth, Katharine J. Parkins, John Gibson |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Hepatology medicine.diagnostic_test business.industry medicine.medical_treatment Gastroenterology Sigmoidoscopy Balsalazide medicine.disease Asymptomatic Ulcerative colitis chemistry.chemical_compound chemistry Mesalazine Internal medicine medicine Colitis medicine.symptom business Adverse effect |
| Zdroj: | Gastroenterology. 114:15-22 |
| ISSN: | 0016-5085 |
| Popis: | Background & Aims: Aminosalicylates are widely used in the treatment of ulcerative colitis (UC). Balsalazide is a novel mesalamine prodrug, activated by colonic bacteria. The aim of this study was to compare the efficacy and safety of balsalazide with that of a pH-dependent formulation of mesalamine in active UC. Methods: A randomized, double-blind study was performed comparing balsalazide, 6.75 g daily, with mesalamine, 2.4 g daily, administered for 4, 8, or 12 weeks to 101 (99 evaluable) patients with symptomatic, sigmoidoscopically verified UC. Results: More patients treated with balsalazide achieved symptomatic remission after 2 (64% [balsalazide] vs. 43% [mesalamine]), 4 (70% vs. 51%), 8 (78% vs. 45%), and 12 weeks (88% vs. 57%) and complete remission (none/mild symptoms, sigmoidoscopy grade 0/1, no rectal steroid use within 4 days) after 4 (38% vs. 12%), 8 (54% vs. 22%), and 12 weeks (62% vs. 37%). Patients taking balsalazide experienced more asymptomatic days (4 weeks, 24% vs. 14%) and achieved the first asymptomatic day more rapidly (median, 10 vs. 25 days). Fewer patients in the balsalazide group reported adverse events (48% vs. 71%); four serious adverse events occurred in the mesalamine group. Conclusions: Balsalazide is more effective and better tolerated than mesalamine as treatment for acute UC. GASTROENTEROLOGY 1998;114:15-22 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|